Drugs - Xagena.net - Update in Medicine

Search results for "Rivaroxaban"

FDA has approved twice-daily Xarelto 2.5-mg dose to reduce the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease

The U.S. Food and Drug Administration ( FDA ) has approved Xarelto ( Rivaroxaban ) to reduce the risk of major cardiovascular events, such as cardiovascular death, myocardial infarction and stroke, in ... read article

COMPASS trial: Rivaroxaban in patients with coronary or peripheral artery disease has shown overwhelming efficacy and has met primary endpoint early

The phase III trial COMPASS evaluating the efficacy and safety of Rivaroxaban ( Xarelto ) for the prevention of major adverse cardiac events ( MACE ) including cardiovascular death, myocardial infarct ... read article

Xarelto for secondary prevention after an acute coronary syndrome, approved in European Union

Xarelto ( Rivaroxaban ), a novel oral anticoagulant, has been approved by the European Commission ( EC ) for the prevention of atherothrombotic events ( cardiovascular death, myocardial infarction or ... read article

NICE recommends Xarelto, the only oral single-drug therapy for the treatment of deep vein thrombosis and prevention of recurrent DVT and pulmonary embolism

Oral anticoagulant Xarelto ( Rivaroxaban ) has been recommended for National Health Service ( NHS ) use in Final Guidance by the United Kingdoms National Institute for Health and Clinical Excellence ... read article

Knee or hip replacement surgery: FDA has approved Xarelto to reduce risk of blood clots

The FDA ( Food and Drug Administration ) has approved Xarelto ( Rivaroxaban ) to reduce the risk of blood clots, deep vein thrombosis, and pulmonary embolism following knee or hip replacement surgery. ... read article

EINSTEIN DVT trial: Rivaroxaban is an effective and safe treatment for acute symptomatic deep vein thrombosis

Results of the Phase III EINSTEIN-DVT study have shown that the oral anticoagulant Rivaroxaban ( Xarelto ) achieved the primary efficacy and safety outcomes in the treatment of patients with acute, sy ... read article

Anticoagulants in the prevention of venous thromboembolism and recurrent miscarriage

Coagulation is an important process that prevents excessive bleeding when a blood vessel is injured. Sometimes, however, clots form on the inside of vessels without an obvious injury or do not dissolv ... read article

Focus

New indication for Eylea in EU: treatment of visual impairment due to macular edema secondary to central retinal vein occlusion

Bayer HealthCare has announced that Eylea ( Aflibercept solution for injection ) has been approved by the European Commission ( EC ) for the treatment of visual impairment due to macular edema seconda ... read article

Ibrutinib shows efficacy as treatment for chronic lymphocytic leukemia and mantle cell lymphoma

Two clinical studies published in the New England Journal of Medicine ( NEJM ) suggest that the novel agent Ibrutinib shows real potential as a safe, effective, targeted treatment for adults with chro ... read article

Olmesartan Medoxomil can cause sprue-like enteropathy

FDA ( Food and Drug Administration ) has warned that the blood pressure drug Olmesartan Medoxomil ( marketed as Benicar, Benicar HCT, Azor, Tribenzor, and generics ) can cause intestinal problems know ... read article

Barrett's esophagus: Acetylsalicylic acid may fight cancer by slowing DNA damage

Aspirin ( Acetylsalicylic acid ) is known to lower risk for some cancers, and a new study led by a UC San Francisco researcher, Carlo Maley, points to a possible explanation, with the discovery that A ... read article

Metastatic or unresectable melanoma: FDA approves Tafinlar and Mekinist

The Food and Drug Administration ( FDA ) has approved two new drugs, Tafinlar ( Dabrafenib ) and Mekinist ( Trametinib ), for patients with advanced ( metastatic ) or unresectable melanoma, the most d ... read article

Giant cell tumor of the bone: FDA approves Xgeva

The Food and Drug Administration ( FDA ) has expanded the use of Xgeva ( Denosumab ) to treat adults and some adolescents with giant cell tumor of the bone ( GCTB ), a rare and usually non-cancerous t ... read article

Riociguat has demonstrated significant and sustained improvements in 6MWD and WHO functional class in patients with pulmonary arterial hypertension

Data from the interim analysis of the on-going PATENT-2 trial with Riociguat, the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Thoracic Societ ... read article

Canagliflozin, a SGLT2 inhibitor, for the treatment of adults with type 2 diabetes

Janssen Pharmaceuticals has announced the FDA ( Food and Drug Administration ) has approved Invokana ( Canagliflozin ) for the treatment of adults with type 2 diabetes. Invokana is the first in a new ... read article